NCT04711759View on ClinicalTrials.gov

Physiologic Effects of High-flow Nasal Cannula Versus Standard Oxygen Therapy Postextubation in Critically Ill Patients

NACompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 27, 2021

Primary Completion Date

November 17, 2022

Study Completion Date

December 17, 2022

Conditions
Ventilator Weaning
Interventions
DEVICE

High flow nasal cannula

High flow nasal cannula will be provided through a commercial device (AIRVO2 + Optiflow nasal cannula, Fisher \& Paykel), at 50 LPM and at the same FiO2 applied during the spontaneous breathing trial.

DEVICE

Standard oxygen therapy

Standard oxygen therapy will be provided through a Venturi mask and O2 flow will be adjusted to keep the same FiO2 applied during the spontaneous breathing trial.

Trial Locations (1)

114D

Hospital Clínico UC Christus, Santiago

All Listed Sponsors
collaborator

Fondo Nacional de Desarrollo Científico y Tecnológico, Chile

OTHER_GOV

lead

Pontificia Universidad Catolica de Chile

OTHER

NCT04711759 - Physiologic Effects of High-flow Nasal Cannula Versus Standard Oxygen Therapy Postextubation in Critically Ill Patients | Biotech Hunter | Biotech Hunter